Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd..
Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto-Abs) to type I IFNs were reported as a risk factor for life-threatening COVID-19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS).
Methods: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay.
Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups.
Conclusion: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 17(2023), 3 vom: 16. März, Seite e13116 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alotaibi, Faizah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.03.2023 Date Revised 05.05.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.13116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354653156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354653156 | ||
| 003 | DE-627 | ||
| 005 | 20231226062659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354653156 | ||
| 035 | |a (NLM)36960162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alotaibi, Faizah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2023 | ||
| 500 | |a Date Revised 05.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. | ||
| 520 | |a Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto-Abs) to type I IFNs were reported as a risk factor for life-threatening COVID-19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS) | ||
| 520 | |a Methods: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay | ||
| 520 | |a Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups | ||
| 520 | |a Conclusion: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a MERS | |
| 650 | 4 | |a MIRACLE trial | |
| 650 | 4 | |a Type I IFNs | |
| 650 | 4 | |a auto‐abs | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Interferon beta-1b |2 NLM | |
| 650 | 7 | |a 145155-23-3 |2 NLM | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Alharbi, Naif Khalaf |e verfasserin |4 aut | |
| 700 | 1 | |a Rosen, Lindsey B |e verfasserin |4 aut | |
| 700 | 1 | |a Asiri, Ayed Y |e verfasserin |4 aut | |
| 700 | 1 | |a Assiri, Abdullah M |e verfasserin |4 aut | |
| 700 | 1 | |a Balkhy, Hanan H |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jeraisy, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Mandourah, Yasser |e verfasserin |4 aut | |
| 700 | 1 | |a AlJohani, Sameera |e verfasserin |4 aut | |
| 700 | 1 | |a Al Harbi, Shmeylan |e verfasserin |4 aut | |
| 700 | 1 | |a Jokhdar, Hani A Aziz |e verfasserin |4 aut | |
| 700 | 1 | |a Deeb, Ahmad M |e verfasserin |4 aut | |
| 700 | 1 | |a Memish, Ziad A |e verfasserin |4 aut | |
| 700 | 1 | |a Jose, Jesna |e verfasserin |4 aut | |
| 700 | 1 | |a Ghazal, Sameeh |e verfasserin |4 aut | |
| 700 | 1 | |a Al Faraj, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Al Mekhlafi, Ghaleb A |e verfasserin |4 aut | |
| 700 | 1 | |a Sherbeeni, Nisreen Murad |e verfasserin |4 aut | |
| 700 | 1 | |a Elzein, Fatehi Elnour |e verfasserin |4 aut | |
| 700 | 1 | |a AlMutairi, Badriah M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Dawood, Abdulaziz |e verfasserin |4 aut | |
| 700 | 1 | |a Abdullah, Mashan L |e verfasserin |4 aut | |
| 700 | 1 | |a Barhoumi, Tlili |e verfasserin |4 aut | |
| 700 | 1 | |a Alenazi, Mohammed W |e verfasserin |4 aut | |
| 700 | 1 | |a Almasood, Abdulrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M |e verfasserin |4 aut | |
| 700 | 0 | |a Saudi Critical Care Trials Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 17(2023), 3 vom: 16. März, Seite e13116 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:3 |g day:16 |g month:03 |g pages:e13116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 3 |b 16 |c 03 |h e13116 | ||